Spectroscopy Expected to Drive Growth in $107B Proteomics Market

News
Article

High-resolution magnetic angle spinning nuclear magnetic resonance (HRMAS NMR) spectroscopy in particular can be applied to nonconventional solvents, helping to obtain information about protein crystal structures while also adhering to green analytical chemistry tenets.

Spectroscopy is predicted to drive 15% growth in the global proteomics market by 2030, pushing the market’s value to $107.66 billion US dollars, according to a recent report by Vantage Market Research. Along with chromatography and electrophoresis, the growth in value of proteomics-related techniques is forecast to enhance a market that was worth an estimated $35.2 billion in 2022.

An illustration of a network of molecules, forming a web-like structure, representing the dynamics of molecular interactions Generative AI | Image Credit: © Denis Yevtekhov - stock.adobe.com

An illustration of a network of molecules, forming a web-like structure, representing the dynamics of molecular interactions Generative AI | Image Credit: © Denis Yevtekhov - stock.adobe.com

A 2021 study in the journal Sustainable Chemistry and Pharmacy elucidated the relationship between spectroscopy and proteomics through the years, pointing to nuclear magnetic resonance (NMR) spectroscopy as a complement to or substitute for X-ray crystallography in the process of obtaining information about protein crystal structures (1). Furthermore, the high-resolution magnetic angle spinning (HRMAS) NMR technique can be applied to nonconventional solvents, aligning it with the practices of green analytical chemistry.

The demand for proteomics has increased over the last several years, according to the Vantage report, because of its role in disease diagnosis, particularly the early detection of cancer. The research firm said that the biomarkers identified by proteomics help to discover therapeutic targets in biospecimens that drive market demand. But proteomics-based solutions, the same report said, reach farther than just cancer detection and treatment. As the frequency of other chronic illnesses such as diabetes and heart disease increase worldwide, the need for customizable medicines that detect protein biomarkers is expected to intensify.

As of 2022, Vantage said, the proteomics market was dominated by North America, with the continent’s 42.3% share of revenue attributed to generally advanced healthcare infrastructure. But trend-watchers say governments primarily in the Asia/Pacific region, like those of China and India, but also in other corners of the world such as Brazil, are now investing heavily in the research and development of new potential drugs as proteomics research and technology continues to transform the pharmaceutical industry. Those are the regions which are forecast to experience the maximum market growth by 2030.

Reference

(1) Mielko, K. A.; Pudełko-Malik, N.; Tarczewska, A.; Młynarz, P. NMR Spectroscopy as a “Green Analytical Method” in Metabolomics and Proteomics Studies. Sustainable Chem. Pharm. 2021, 22, 100474. DOI: 10.1016/j.scp.2021.100474